These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 20211908)

  • 1. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial.
    Ristori G; Romano S; Visconti A; Cannoni S; Spadaro M; Frontali M; Pontieri FE; Vanacore N; Salvetti M
    Neurology; 2010 Mar; 74(10):839-45. PubMed ID: 20211908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial.
    Romano S; Coarelli G; Marcotulli C; Leonardi L; Piccolo F; Spadaro M; Frontali M; Ferraldeschi M; Vulpiani MC; Ponzelli F; Salvetti M; Orzi F; Petrucci A; Vanacore N; Casali C; Ristori G
    Lancet Neurol; 2015 Oct; 14(10):985-91. PubMed ID: 26321318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
    Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC;
    Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial.
    Coarelli G; Heinzmann A; Ewenczyk C; Fischer C; Chupin M; Monin ML; Hurmic H; Calvas F; Calvas P; Goizet C; Thobois S; Anheim M; Nguyen K; Devos D; Verny C; Ricigliano VAG; Mangin JF; Brice A; Tezenas du Montcel S; Durr A
    Lancet Neurol; 2022 Mar; 21(3):225-233. PubMed ID: 35063116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial.
    Feil K; Adrion C; Teufel J; Bösch S; Claassen J; Giordano I; Hengel H; Jacobi H; Klockgether T; Klopstock T; Nachbauer W; Schöls L; Stendel C; Uslar E; van de Warrenburg B; Berger I; Naumann I; Bayer O; Müller HH; Mansmann U; Strupp M
    BMC Neurol; 2017 Jan; 17(1):7. PubMed ID: 28068987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability and validity of ICARS in focal cerebellar lesions.
    Schoch B; Regel JP; Frings M; Gerwig M; Maschke M; Neuhäuser M; Timmann D
    Mov Disord; 2007 Nov; 22(15):2162-9. PubMed ID: 17712842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial.
    Fehlings MG; Nakashima H; Nagoshi N; Chow DS; Grossman RG; Kopjar B
    Spinal Cord; 2016 Jan; 54(1):8-15. PubMed ID: 26099215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrotendinous Xanthomatosis ataxia responsive to CDCA and Riluzole.
    Weissfeld T; Ratliff J
    J Clin Neurosci; 2018 Jul; 53():263-264. PubMed ID: 29731275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Acetyl-DL-Leucine in Certain Types of Cerebellar Ataxia: The ALCAT Randomized Clinical Crossover Trial.
    Feil K; Adrion C; Boesch S; Doss S; Giordano I; Hengel H; Jacobi H; Klockgether T; Klopstock T; Nachbauer W; Schöls L; Steiner KM; Stendel C; Timmann D; Naumann I; Mansmann U; Strupp M;
    JAMA Netw Open; 2021 Dec; 4(12):e2135841. PubMed ID: 34905009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of cerebellar ataxia in chronic alcoholics using the International Cooperative Ataxia Rating Scale (ICARS).
    Fitzpatrick LE; Jackson M; Crowe SF
    Alcohol Clin Exp Res; 2012 Nov; 36(11):1942-51. PubMed ID: 22568470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the International Cooperative Ataxia Scale rating in multiple system atrophy.
    Tison F; Yekhlef F; Balestre E; Chrysostome V; Quinn N; Wenning GK; Poewe W
    Mov Disord; 2002 Nov; 17(6):1248-54. PubMed ID: 12465064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.
    Pandolfo M; Arpa J; Delatycki MB; Le Quan Sang KH; Mariotti C; Munnich A; Sanz-Gallego I; Tai G; Tarnopolsky MA; Taroni F; Spino M; Tricta F
    Ann Neurol; 2014 Oct; 76(4):509-21. PubMed ID: 25112865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial.
    Winner P; Pearlman EM; Linder SL; Jordan DM; Fisher AC; Hulihan J;
    Headache; 2005; 45(10):1304-12. PubMed ID: 16324162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Glutamate Modulators in Tic Suppression: A Double-Blind, Randomized Control Trial of D-serine and Riluzole in Tourette Syndrome.
    Lemmon ME; Grados M; Kline T; Thompson CB; Ali SF; Singer HS
    Pediatr Neurol; 2015 Jun; 52(6):629-34. PubMed ID: 26002052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial.
    Meininger V; Asselain B; Guillet P; Leigh PN; Ludolph A; Lacomblez L; Robberecht W;
    Neurology; 2006 Jan; 66(1):88-92. PubMed ID: 16401852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study.
    Bier JC; Dethy S; Hildebrand J; Jacquy J; Manto M; Martin JJ; Seeldrayers P
    J Neurol; 2003 Jun; 250(6):693-7. PubMed ID: 12796831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension.
    Giorgi L; Asgharian A; Hunter B
    Clin Ther; 2013 Sep; 35(9):1321-36. PubMed ID: 23938061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.